Observation, Laser, Injections or Surgery: How Diabetic Retinopathy Treatment Is Chosen

The letter arrives two weeks after the screening visit, and one word stands out: retinopathy. Nothing feels different. The kitchen clock reads the same, the newspaper is no blurrier than yesterday. Yet the note asks for an appointment with an eye specialist, and a quiet question settles in: does this mean laser, needles, an operation, or nothing at all?

That uncertainty is common, because the range of diabetic retinopathy treatment options is wide and the choice depends less on how a person feels than on what a camera and a scanner show at the back of the eye. Two people can sit in the same waiting room with the same diagnosis and leave with different plans: one is told to come back in a year, the other is booked for an injection the same afternoon.

This explainer walks through how those decisions are made, what each option involves, and what the days afterward tend to look like, so the conversation with the care team starts from understanding rather than fear.

What diabetic retinopathy actually does to the eye

The retina is the light-sensing layer at the back of the eye, about the thickness of a sheet of paper, fed by a dense web of tiny blood vessels. Years of raised blood sugar damage the walls of those vessels. Some leak fluid and fat, some close off entirely, and the retina begins to starve for oxygen.

Eye specialists describe the damage in stages. The early stages are called nonproliferative, meaning no new vessels have grown yet; the retina shows small bulges in vessel walls, tiny bleeds and patches of leakage. When enough of the retina is starved, the tissue releases a signal protein called vascular endothelial growth factor, or VEGF, which tells the eye to grow new vessels. This is the proliferative stage. The new vessels sound like a rescue but they are flimsy, grow in the wrong place, bleed easily and pull scar tissue with them. The National Eye Institute lays out these stages in plain language.

Running alongside the stages is a separate problem: diabetic macular edema. The macula is the small central patch of the retina responsible for reading, faces and fine detail, and edema means swelling from leaked fluid. Macular edema can appear at any stage, which is why a person with otherwise mild retinopathy may still need active treatment.

The reason none of this is felt early is that the retina has no pain fibers and the brain fills in small gaps. Vision usually changes only when the macula swells, when a new vessel bleeds into the jelly of the eye, or when scar tissue pulls the retina out of place. That silence is the whole argument for regular screening, which the NHS offers to everyone with diabetes from age 12.

The four diabetic retinopathy treatment options, in one view

People often imagine treatment as a ladder that everyone climbs in the same order. In practice the four approaches map onto different problems in the eye, and a specialist may use one, two or three of them over the years, sometimes in the same eye. The table below summarizes what each is for, drawing on descriptions from the Mayo Clinic and the NHS.

Option	Main target	Where it is done	What it commonly involves
Observation	Mild to moderate nonproliferative disease without macular edema	Screening program and clinic	Retinal photographs and scans at set intervals, plus blood sugar, blood pressure and cholesterol control
Laser	New, fragile vessels (proliferative disease); some cases of leakage away from the center	Outpatient clinic chair	Numbing drops, a contact lens on the eye, brief bright flashes; often more than one session
Anti-VEGF injections	Diabetic macular edema; increasingly, proliferative disease	Outpatient clinic	Numbing drops, antiseptic, a very fine needle into the white of the eye; repeated at intervals
Vitrectomy surgery	Bleeding into the eye that does not clear, scar tissue, traction on the retina	Operating room	Removal of the vitreous jelly, clearing blood, peeling scar tissue, laser inside the eye

Notice what the table does not contain: a rank order. Injections are not “more advanced” than laser, and surgery is not a failure of the other options. Each addresses a different piece of anatomy. The most useful question to bring to the specialist is therefore not “which is best” but “what exactly is happening in my eye, and which of these speaks to that problem”.

Why doing nothing yet is a real treatment: observation and monitoring

Being told to come back in a year can feel like being dismissed. It is the opposite. Observation is the option most people with diabetic retinopathy are given, and it carries its own set of responsibilities and safeguards.

The logic is straightforward. Laser and injections each carry small but real risks, and in mild nonproliferative disease there is nothing for them to fix: no new vessels to close, no central swelling to dry. Treating a retina that is not yet threatening sight would add risk without benefit. Meanwhile the factors that decide whether the disease progresses live outside the eye entirely, in blood sugar, blood pressure and cholesterol.

Observation is not passive. It typically means retinal photographs at each screening visit, and for some people an optical coherence tomography scan, or OCT, a painless scan that produces a cross-section of the retina and measures its thickness to within a few thousandths of a millimeter. The NHS describes how screening results are graded and how people with more changes are recalled sooner or referred to a hospital eye clinic. In the United States, MedlinePlus recommends a dilated eye examination at least once a year for people with diabetes.

The interval matters because retinopathy can move. A retina graded as moderate nonproliferative disease may show new vessels within months if glucose control slips, or may stay unchanged for a decade if it holds. Missing a recall is the single most common way observation goes wrong, because the disease advances silently and the next symptom may be a bleed.

If the plan is observation, it is reasonable to ask two things: what would move me into active treatment, and how will you know. A clear answer to both usually settles the anxiety that the word “wait” tends to stir.

Who is usually treated, and who is usually asked to wait

Two findings on the scan tend to tip a person from monitoring into active treatment, and the NHS names them: proliferative retinopathy, where new vessels have appeared, and diabetic maculopathy, where swelling or leakage threatens the center of vision. When either is present, the specialist is usually weighing which treatment rather than whether to treat.

Severe nonproliferative disease sits in a gray zone. The retina is heavily starved and new vessels are likely soon, but have not yet formed. Some specialists treat early, especially if the person struggles to attend follow-up or has only one good eye; others monitor closely at short intervals. Both are defensible, and the choice often turns on practicalities as much as on the pictures.

People commonly asked to wait include those with:

• Mild or moderate nonproliferative changes and a normal macular thickness on OCT
• Small amounts of leakage well away from the center of the macula
• Recently improved blood sugar or blood pressure control, where the retina may settle on its own

A few situations change the calculus in the other direction. Pregnancy can speed up retinopathy, so the NHS arranges additional screening during pregnancy. Cataract surgery can worsen macular edema, so an eye specialist may want swelling treated first. Rapid tightening of blood sugar after years of high readings can also cause a temporary worsening, which is one reason the diabetes and eye teams talk to each other.

What does not decide treatment is how the person feels. Someone reading comfortably may need injections because the scan shows fluid creeping toward the center; someone with floaters from an old bleed may need nothing more than time. The images lead, symptoms follow, and the final call rests with the treating team.

Laser treatment for diabetic retinopathy: what happens in the chair

Laser was the first treatment shown to protect sight in diabetic retinopathy, and it remains a mainstay for proliferative disease. Its job is counterintuitive: it deliberately sacrifices some of the starving outer retina so that the tissue stops producing VEGF, and the fragile new vessels shrink back. The center of vision is left untouched.

The Mayo Clinic describes two forms. Focal or grid laser treats specific leaking spots away from the center and is usually completed in a single session. Panretinal photocoagulation, often shortened to PRP, scatters hundreds to a few thousand tiny burns across the peripheral retina and is usually done in two or more sessions.

The experience itself is undramatic. Numbing drops go in, a contact lens is placed on the eye to hold it steady and focus the beam, and the person rests their chin on a frame while looking at a target light. Each pulse is a brief bright flash. Many people describe a dull ache or a sensation like a small pinch toward the end of a long PRP session; a few find it uncomfortable enough that the specialist numbs the eye with an injection behind it.

Vision is typically blurry for about a day afterward according to the Mayo Clinic, and the NHS advises arranging transport home and expecting some light sensitivity. The lasting trade-offs of PRP are real and should be discussed honestly: reduced night vision, some loss of the outer edges of the visual field, and occasionally a fixed blind spot or a pattern noticed when looking at plain surfaces. For most people these are accepted because the alternative, untreated proliferative disease, risks far more. The specialist should explain how the peripheral field loss may affect driving standards where the person lives.

Anti-VEGF injections for diabetic retinopathy: how a shot in the eye works

The phrase “injection into the eye” stops most conversations. It helps to know what the needle is doing and where it goes.

Anti-VEGF medicines are a class of drugs that bind the growth factor VEGF and neutralize it. In macular edema, VEGF is the main driver of leakage, so blocking it lets the vessels seal and the retina dry out. In proliferative disease it starves the new vessels of their signal so they regress. The National Eye Institute notes that these medicines can slow or reverse retinopathy, which is why they have become the usual first choice for swelling at the center of vision.

The injection goes through the white of the eye, the sclera, into the vitreous, the clear jelly filling the back of the eye, a few millimeters from the edge of the colored iris. The eye is numbed with drops or gel, cleaned with antiseptic and held open with a small spring clip. Most people report pressure rather than pain, and the actual injection takes a few seconds. A gritty sensation and a red patch on the white of the eye are common for a day or two afterward.

Repetition is the part people find hardest. The medicine is cleared from the eye over weeks, so the NHS describes injections given roughly once a month to begin with, then spaced out or stopped once the retina stabilizes. Exact scheduling is individual, guided by repeat OCT scans, and set by the prescribing specialist.

Risks are uncommon but worth knowing. The NHS lists eye irritation, bleeding inside the eye, floaters, and a small risk of infection or retinal detachment. Infection inside the eye, called endophthalmitis, is rare but serious, which is why any increasing pain, redness or vision loss in the days after an injection needs same-day attention rather than a wait-and-see approach.

Diabetic macular edema treatment: why the center of vision gets its own plan

Macular edema behaves differently from the rest of retinopathy, so it earns a separate line in the plan. The macula is only a few millimeters across, yet it carries the detail vision a person notices most. Fluid pooling there blurs reading, dulls colors and can bend straight lines. Unlike peripheral changes, macular edema usually produces symptoms, and people often arrive already worried.

The OCT scan is the referee here. It shows whether fluid is present, how thick the retina has become, and crucially whether the very center, the fovea, is involved. The NHS explains that anti-VEGF injections are the usual treatment when swelling involves or threatens the center, and that laser may be used when leakage sits away from it.

Why not laser the center? Laser destroys the tissue it treats. Burns close to the fovea would trade one blind spot for another. Injections, by contrast, dry the retina without destroying it, which is why they overtook laser as the first choice for center-involving edema. Focal laser still has a place for leaking spots at a safe distance, and some specialists combine the two.

Timelines are gradual. Fluid often begins to recede within weeks of the first injection, but visual improvement can lag behind the scan, and a retina that has been swollen for a long time may not recover fully even once dry. The Mayo Clinic is careful to say that treatment slows or stops progression and does not restore what has already been lost, which is a fair summary of what the evidence shows.

Systemic control matters here too. Persistently high blood pressure keeps pushing fluid into the retina no matter how many injections are given, and the diabetes team’s work on blood pressure and kidney health is part of macular edema treatment even though it never touches the eye.

Steroid implants and other options when injections are not enough

Not every macula dries out with anti-VEGF alone. Some people have persistent fluid after a run of injections, some cannot attend monthly, and some have inflammation driving the leakage more than VEGF does. The NHS and the Mayo Clinic both describe corticosteroid implants as an alternative in these situations.

Corticosteroids are a class of anti-inflammatory medicine. Inside the eye they reduce leakage through several pathways at once, not just VEGF, and a slow-release implant placed through a fine needle can keep working for months rather than weeks. That longer interval is the appeal for people who find frequent visits impossible.

The trade-offs are specific and well documented. Steroids raise pressure inside the eye in a proportion of people, which may need drops or, rarely, a pressure-lowering procedure. They also accelerate cataract, the clouding of the eye’s natural lens, in eyes that still have their own lens. For that reason specialists often reserve steroid implants for eyes that have already had cataract surgery or for people in whom anti-VEGF has not delivered.

Beyond steroids, the other supporting options are less about new drugs and more about combination and sequencing:

• Combining anti-VEGF with focal laser to reduce the number of injections needed over time
• Switching between anti-VEGF agents within the class when one gives a partial response
• Treating proliferative disease with anti-VEGF alone, with PRP, or with both, depending on how reliably the person can attend

None of these is a recommendation; each is a fork the specialist may raise. The practical point is that a partial response to the first plan does not mean running out of road. It means a different conversation, ideally one where the person’s ability to attend and their other health conditions are on the table alongside the scan.

Vitrectomy for diabetic retinopathy: when surgery enters the conversation

Surgery is rarely the opening move. Vitrectomy is reserved for problems that laser and injections cannot reach: a bleed into the vitreous that will not clear, scar tissue pulling on the retina, or a retina already lifting away, called a tractional detachment. The NHS lists these as the usual reasons.

The vitreous is the clear jelly that fills the back of the eye. In advanced retinopathy it becomes the scaffold that new vessels grow along and the reservoir that blood pools in. Removing it removes both. During a vitrectomy the surgeon makes three tiny openings in the white of the eye, replaces the jelly with a clear fluid, clears away blood, peels membranes of scar tissue off the retina, and often applies laser from inside. At the end the eye may be filled with saline, a temporary gas bubble, or silicone oil to hold the retina flat.

The Mayo Clinic notes the procedure is done under local or general anesthesia, usually as a day case. Afterward the eye is padded, and the NHS advises expecting blurred vision for a period that varies from days to weeks depending on what was done, along with soreness and restrictions on activity.

Two details catch people out. A gas bubble blurs vision until it absorbs, over days to several weeks, and while it is present flying or traveling to high altitude is unsafe because the bubble expands as air pressure drops; the surgeon gives specific guidance on when it has gone. Silicone oil usually requires a second operation to remove it.

Risks include bleeding, infection, raised eye pressure, retinal detachment and, in eyes with their own lens, cataract. Surgery can stabilize an eye and clear the view, but how much sight returns depends on how healthy the retina underneath was, which is why the decision belongs to the retinal surgeon and the person together.

How the eye team decides between diabetic retinopathy treatment options

Watching a specialist flick between images and pronounce a plan in minutes can feel like magic. It is closer to a checklist, run in a particular order.

The first question is whether new vessels are present. If yes, the eye is proliferative and needs active treatment, usually PRP laser, anti-VEGF injections or both. The second question is whether the macula is swollen, and if so whether the center is involved. Center-involving edema usually points to injections; leakage away from the center may point to focal laser or watchful waiting. The third question is whether anything mechanical has happened: blood filling the vitreous, scar tissue, or traction. Those point toward surgery.

Then come the modifiers that textbooks list but people rarely hear about:

• How reliably can this person attend? Monthly injections protect sight only if they happen. Someone who lives far away, cares for others or cannot take time off may be better served by laser, which needs fewer visits.
• What is the other eye doing? Specialists are more cautious with an only good eye and may treat earlier.
• Is cataract surgery or pregnancy on the horizon? Both can accelerate retinopathy and shift timing.
• How is the kidney and blood pressure picture? Poorly controlled hypertension undermines every eye treatment.
• What has this eye already had? A retina treated with PRP years ago responds differently from an untreated one.

The Mayo Clinic frames the goal of all treatment as slowing or stopping progression, and the CDC stresses that early detection and treatment are what prevent blindness. Neither presents any one option as the right answer for everyone, and neither should a clinic. If the reasoning behind a plan is not clear, asking the specialist to walk through these questions aloud is entirely reasonable.

What the days and weeks after treatment usually look like

Recovery differs so much between the options that it deserves its own map. What follows draws on the NHS and Mayo Clinic descriptions; individual experience varies and the treating team’s instructions override any general guide.

After laser, the dilating drops leave vision blurred and light-sensitive for several hours, and the Mayo Clinic describes blurriness lasting about a day. A dull ache is common the evening of a long PRP session. Driving is off the table until vision clears, and most people return to normal activity the next day. Night vision changes after PRP, if they occur, settle into a new normal over weeks rather than improving.

After an anti-VEGF injection, the eye is often gritty and red for a day or two, and a floater from a tiny air bubble or the medicine itself may drift for a few hours. The NHS notes that the injections take time to work, with improvement judged on repeat scans over the following weeks rather than on the walk home. The schedule for the next visit is set before leaving, because the interval is part of the treatment.

After vitrectomy, the eye is padded overnight and reviewed the next day. Soreness, watering and blurred vision are expected. If a gas bubble was placed, the surgeon may ask for specific head positioning for several days and will forbid flying until the bubble is gone. Drops to prevent infection and inflammation are used for weeks. Vision improves as the bubble absorbs and swelling settles, over weeks to a few months, and only then does the surgeon judge the final result.

Across all three, the common thread is follow-up. Every treatment is judged by the next scan, not by the moment the person stands up from the chair.

Blood sugar, blood pressure and the treatment you do at home

Laser, injections and surgery treat the consequences of diabetic retinopathy. They do not touch the cause. The treatment that shapes the long arc of the disease happens at the kitchen table, the pharmacy and the diabetes clinic, and every eye specialist knows it.

Three numbers carry most of the weight. Blood glucose, tracked over months by the HbA1c test, drives the vessel damage in the first place. Blood pressure pushes fluid through weakened vessel walls and is a major driver of macular edema. Blood lipids, particularly cholesterol, contribute to the fatty deposits that leak into the retina. The NHS and MedlinePlus both put control of these three at the center of preventing progression.

Two cautions keep this from becoming a lecture. First, targets are individual. The right HbA1c for a young adult with new type 1 diabetes is not the right one for an older person with heart disease, and the diabetes team sets it, not the eye clinic. Second, tightening control very quickly after years of high readings can temporarily worsen retinopathy, which is a reason for coordinated care rather than a reason to avoid improvement; specialists may simply watch the retina more closely during that transition.

Smoking damages the same small vessels and is worth raising with the diabetes team, which can point to support. Kidney function deserves a mention too: retinopathy and diabetic kidney disease travel together, and treating one often helps the other.

The practical translation is that the person receiving injections is not a passive recipient. Attending the diabetes review, taking prescribed medicines as directed by the prescribing clinician, and keeping blood pressure in the agreed range are as much part of retinopathy care as anything done under the microscope. Any change to those medicines should go through the doctor who prescribes them.

What people often get wrong about diabetic retinopathy treatment

Myths gather around any condition that involves needles and eyes. Several are worth dismantling because they change behavior.

“If my vision is fine, my retina is fine.” The National Eye Institute is explicit that early stages produce no symptoms. New vessels can grow across the peripheral retina without any change in reading vision. Screening exists because feeling fine tells the specialist nothing.

“Laser will make me blind.” PRP does reduce peripheral and night vision, and specialists should say so. It does this to protect central sight from a far larger threat. The trade is deliberate and, in proliferative disease, well supported by decades of evidence summarized on the Mayo Clinic pages.

“Injections are a one-time fix.” Anti-VEGF medicines wear off. The NHS describes a course beginning roughly monthly and tapering as the retina settles. Treating injections as a single event and skipping the follow-up is a common route to recurrent swelling.

“Treatment will give me back the vision I had.” Sometimes vision improves, particularly when edema is dried early. Often the honest goal is holding steady. The Mayo Clinic frames treatment as slowing or stopping progression, and that is the fair expectation to carry into the clinic.

“Surgery means the doctors gave up.” Vitrectomy is a specific tool for specific mechanical problems, not a last resort after failure. Many people who have it never needed laser or injections first because a bleed was their first sign.

“Good blood sugar means I can skip the eye checks.” Good control lowers risk; it does not remove it. Duration of diabetes matters on its own, and screening remains the safety net regardless of how the numbers look.

Questions to ask your care team

Appointments are short and the words are unfamiliar. A written list changes the dynamic. These questions are phrased so that the answers, whatever they are, leave the person understanding their own plan.

• What stage is my retinopathy in each eye, and is there any swelling at the center of the macula?
• If the plan is to monitor, what finding would move me to active treatment, and how often will I be scanned?
• If treatment is proposed, which problem in my eye is it addressing: new vessels, central swelling, or a mechanical issue such as bleeding or scar tissue?
• What are the alternatives to the option you are suggesting, and why do you favor this one for me?
• How many visits does this plan likely involve over the next year, and what happens if I cannot attend one?
• What should I expect to see and feel in the first day, the first week, and the first month afterward?
• Which symptoms after treatment mean I should call the same day?
• How will this treatment affect driving, night vision or my ability to work, and for how long?
• Is there anything about my blood pressure, kidney function or planned cataract surgery that changes the timing?
• Who coordinates between the eye clinic and my diabetes team, and how do they share results?

Bringing a companion helps; the dilating drops used for examination blur vision for hours, and a second pair of ears catches what the first misses. Asking for a printed summary of the plan, or for the OCT image to be shown on screen and explained, is normal and most specialists welcome it. The Cleveland Clinic offers a plain-language overview that can serve as a reference between visits.

None of these questions second-guesses the specialist. They simply make the reasoning visible, which is what informed consent is supposed to mean.

When to call your doctor

Diabetic retinopathy is mostly a slow disease, which is why the exceptions matter. A handful of changes should prompt a same-day call to the eye clinic or, out of hours, an urgent care or emergency service, whether or not treatment has recently been given.

• A sudden shower of new floaters, dark specks or cobweb shapes drifting across vision, which can signal a bleed into the vitreous
• Flashes of light, especially at the edge of vision
• A dark curtain or shadow moving across part of the visual field, a classic sign of retinal detachment
• Sudden loss or marked blurring of vision in one eye
• Straight lines appearing bent or wavy, or a rapid change in reading vision, which may indicate worsening macular edema

After an injection or surgery, add these to the list, because they can indicate infection inside the eye or raised pressure, both of which are treatable but time-sensitive:

• Pain that increases rather than eases over the first two to three days
• Redness that spreads or deepens, particularly with discharge
• Vision that gets worse instead of gradually better
• Nausea or headache with a hard, aching eye

The NHS and MedlinePlus both advise seeking prompt care for sudden visual changes in anyone with diabetes. Waiting to see whether it clears is the wrong instinct with the retina, because detached or oxygen-starved retinal tissue does not wait.

Less urgent but still worth a call within days: a missed screening or injection appointment, a new pregnancy, a planned cataract operation, or a large change in blood sugar or blood pressure medicines made by another clinician. Each can shift the timing of eye care, and the treating team would rather hear about it early than discover it on the next scan.

Frequently asked questions

What are the main diabetic retinopathy treatment options?

There are four: observation with regular scans, laser, anti-VEGF injections and vitrectomy surgery. Observation suits early disease without central swelling. Laser targets new fragile vessels and some leakage away from the center. Injections are the usual first-line treatment for macular edema. Surgery is reserved for bleeding that does not clear, scar tissue or a detaching retina. Many people use more than one over the years, and the treating team makes the choice.

How does laser treatment for diabetic retinopathy work?

Laser creates tiny burns in the oxygen-starved outer retina so that it stops producing VEGF, the signal that drives fragile new vessels to grow. Focal laser treats specific leaking spots away from the center, often in one session, while panretinal photocoagulation scatters many burns across the periphery over two or more sessions according to the Mayo Clinic. Vision is usually blurry for about a day, and some peripheral and night vision may be permanently reduced.

Do anti-VEGF injections for diabetic retinopathy hurt?

Most people describe pressure rather than pain. The eye is numbed with drops or gel and cleaned with antiseptic, and the injection itself lasts a few seconds. A gritty feeling, watering and a red patch on the white of the eye are common for a day or two. Increasing pain, spreading redness or worsening vision in the days afterward are not expected and should be reported to the clinic the same day.

How often are injections needed?

The NHS describes anti-VEGF injections given roughly once a month to begin with, then spaced out or stopped once the retina has stabilized on repeat scans. The exact interval is individual, guided by optical coherence tomography measurements of retinal thickness, and set by the prescribing specialist. Some people need treatment for a long period; others taper quickly. Missing scheduled visits is a common reason swelling returns.

What is diabetic macular edema treatment, and why is it different?

Macular edema is swelling from leaked fluid at the center of the retina, the part used for reading and detail. It is treated separately because laser would destroy central tissue, so anti-VEGF injections are usually first choice when the center is involved; focal laser or steroid implants are alternatives in specific situations. Fluid often recedes over weeks, but vision may lag behind the scan and long-standing swelling may not fully recover.

When is vitrectomy for diabetic retinopathy recommended?

Vitrectomy is usually considered when there is bleeding into the vitreous jelly that does not clear, scar tissue pulling on the retina, or a tractional retinal detachment. The surgeon removes the jelly, clears blood, peels scar tissue and often applies laser from inside the eye. It is done under local or general anesthesia, and recovery of vision takes weeks to months. It is a specific tool for mechanical problems, not a sign that other treatments have failed.

Can diabetic retinopathy be reversed with treatment?

Treatment aims to slow or stop progression and protect the sight a person still has. The National Eye Institute notes that anti-VEGF injections can slow or in some cases reverse retinopathy changes, and drying macular edema early may improve vision. Damage from long-standing swelling, oxygen-starved retina or scar tissue is generally not recoverable. The Mayo Clinic frames the realistic goal as stabilization rather than restoration.

Why was I told to just wait and come back later?

Mild or moderate nonproliferative retinopathy without central swelling has nothing for laser or injections to fix, so treating it would add risk without benefit. Observation means regular photographs and scans to catch progression, alongside blood sugar and blood pressure control, which are what actually change the disease at this stage. It is reasonable to ask what finding would trigger treatment and how often you will be reviewed.

Does better blood sugar control mean I can stop eye treatment?

No. Good glucose, blood pressure and cholesterol control lower the risk of progression and are part of treatment, but they do not remove existing new vessels or dry established swelling on their own. Decisions about continuing, pausing or stopping laser, injections or follow-up scans belong to the eye specialist, based on what the retina shows. Changes to diabetes medicines should go through the clinician who prescribes them.

Can I fly after diabetic retinopathy treatment?

After laser or injections, flying is generally not restricted once vision has cleared enough to travel safely, though the clinic should confirm. After vitrectomy with a gas bubble, flying and high altitude are unsafe until the bubble has fully absorbed, because it expands as cabin pressure falls and can raise eye pressure dangerously. The surgeon will say when it has gone. Arranging follow-up before any travel is essential.

References

• NHS: Diabetic retinopathy, treatment
• NHS: Diabetic retinopathy
• National Eye Institute (NIH): Diabetic retinopathy
• MedlinePlus: Diabetic eye problems

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.